Physician profile
Mohamed Eisa
NPI 1558713057
$17,426.14
in general payments reported to CMS, 2019-2025
24 companies · $2,041 in 2025
The $2,041 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $962 · 2023: $1,032 · 2024: $13K · 2025: $2,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $3,940 · Travel and Lodging: $2,092 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,105.00 |
| Food and Beverage | $3,940.29 |
| Travel and Lodging | $2,091.71 |
| Education | $102.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $11,866.99 | 2024 | Voquezna |
| Boston Scientific Corporation | $1,872.92 | 2024-2025 | Spyglass, Overstitch Endoscopic Suturing System, Apollo 2-0 Polypropylene Endobariatric Suture |
| Abbvie INC. | $1,113.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $460.27 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $420.12 | 2022-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $291.42 | 2023-2024 | Stelara, Tremfya |
| Ferring Pharmaceuticals INC. | $206.87 | 2023-2025 | Rebyota |
| Medtronic, INC. | $184.08 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.06 | 2022-2024 | Xifaxan, Trulance |
| Enterra Medical, INC. | $175.56 | 2025 | |
| Eisai INC. | $124.74 | 2022 | |
| Olympus America INC. | $108.68 | 2023 | Endoclot Sis, Endoclot Phs |
| Steris Corporation | $80.69 | 2024 | |
| Braintree Laboratories, INC. | $76.62 | 2022-2024 | Sutab, Suflave |
| Ardelyx, INC. | $68.92 | 2023-2024 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $56.61 | 2025 | Rezdiffra |
| Genzyme Corporation | $23.32 | 2023 | |
| Celltrion USA INC. | $22.03 | 2024 | Zymfentra |
| Pfizer INC. | $19.98 | 2024 | |
| Nestle Healthcare Nutrition INC. | $19.17 | 2022 | |
| Merck Sharp & Dohme LLC | $14.81 | 2023 | Dificid |
| Celgene Corporation | $13.35 | 2024 | Zeposia |
| Redhill Biopharma INC. | $13.29 | 2022 | |
| Organon LLC | $12.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Eisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.